Adverse Event reporting can be found in the footer.
LATEST NEWS
Join us at UKKW 2026!
Attend our symposium: Rethinking IgA Nephropathy: Early Disease-Modifying Therapy and the Priority of eGFR Stabilisation
Presented by Prof. Jonathan Barratt, Prof. Smeeta Sinha and Dr. Chee Kay Cheung
Tuesday 10th March | 17:15-18:15
Harrogate Convention Centre | Hall D
And visit us at Stand P3
NICE releases new guideline for the treatment of primary IgA nephropathy
New NICE guideline recommends Kinpeygo® ▼ 4mg (modified-release hard capsules budesonide) as an option to treat primary IgA nephropathy in adults when they have a urine protein-to-creatinine ratio (UPCR) of 90 mg/mmol or more, or a protein excretion of 1.0 g/day or more, and as an add-on to optimised standard care.
Prescribing Information can be found here
Updated KDIGO Guideline recommends disease-modifying treatment alongside traditional RASi and SGLT2i
Treatment recommendations emphasise both the prevention of IgA-containing immune complex injury and the management of kidney damage, with detailed guidance on therapies including ACE inhibitors or ARBs, Kinpeygo® ▼ 4mg (modified-release hard capsules budesonide), sparsentan, and sodium-glucose co-transporter-2 inhibitors.
Prescribing Information can be found here
UZPRUVO▼ STADA’s ustekinumab biosimilar is now available
As part of STADA’s commitment to caring for people’s health and supporting the NHS in its mission to provide high quality healthcare to all patients across the UK, we have now entered the global biosimilar pipeline for immunology.
Prescribing information can be found here
STADA UK set for Kidney Week Symposium following successful Kinpeygo®▼ 4mg (modified-release hard capsules budesonide) launch and patients starting treatment
As part of STADA’s commitment to caring for people’s health and supporting the NHS in its mission to provide high quality healthcare to all patients across the UK, we have now entered the global biosimilar pipeline for immunology.
Prescribing information can be found here
Press Release: STADA UK welcomes NICE recommendation of Kinpeygo®▼4mg (modified-release hard capsules budesonide)
First-ever NICE guidance on treating primary IgA nephropathy recommends Kinpeygo® (modified-release hard capsules budesonide) capsules as “an acceptable use of NHS resources” in England and Wales.
Prescribing Information can be found here
Find out more about Kinpeygo® – request a visit from our Medical Science Liaison Team or Healthcare Partnership Manager Team
STADA Specialty Care
Discover more about a rapidly expanding portfolio of high-quality biosimilar medicines
Information
For information on our products please visit EMC, https://www.medicines.org.uk/emc/ and search the product for a Summary of Product Characteristics
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164.
UK-MULT-122c(7) | March 2026